HTR1B
ENSG00000135312
Target class
GPCR
Chromosome
6
Approved drugs
12
Clinical candidates (approved and in development)
16
- Approved drugs
- 12
- Clinical candidates (approved and in development)
- 16
- Chemical probe available
- No
- Target name
- HTR1B
- Gene name
- 5-hydroxytryptamine receptor 1B
- Gene symbol
- HTR1B
- Protein name
- 5-hydroxytryptamine receptor 1B (5-HT-1B) (5-HT1B) (S12) (Serotonin 1D beta receptor) (5-HT-1D-beta) (Serotonin receptor 1B)
- S12
- 5-HT1B
- HTR1D2
- 5-HT1DB
- Gene biotype
- Protein coding
- Gene family
- 5-hydroxytryptamine receptors, G protein-coupled
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 15
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 20.65
- Tissue specificity (Gini)
- 0.747
- Tissue specificity (tau)
- 0.942
- KEGG gene identifiers
- hsa:3351
- Protein interaction confidence
- 0.793156
- Protein interaction partners
- 32
- R-HSA-390666
- R-HSA-418594
- End position
- 77463491
- Start position
- 77460924
- Chromosome
- 6
- Strand
- Reverse
- Cell membrane
- Multi-pass membrane protein .
- Endoplasmic reticulum
- Plasma membrane
- PubMed 10452531
- PubMed 1315531
- PubMed 1328844
- PubMed 1348246
- PubMed 1351684
- PubMed 1559993
- PubMed 1565658
- PubMed 1610347
- PubMed 23519210
- PubMed 23519215
- Tissue specificity (tau)
- 0.941816
- Expression inequality (Gini)
- 0.74705
Expression in transcripts per million
- Artery - Tibial
- 20.65
- Artery - Aorta
- 11.68
- Artery - Coronary
- 11
- Cells - Cultured fibroblasts
- 8.9
- Brain - Nucleus accumbens (basal ganglia)
- 3.14
Expression in transcripts per million
- Artery - Tibial20.65
- Artery - Aorta11.68
- Artery - Coronary11
- Cells - Cultured fibroblasts8.9
- Brain - Nucleus accumbens (basal ganglia)3.14
- Bladder2.41
- Esophagus - Muscularis2.33
- Esophagus - Gastroesophageal Junction2.06
- Testis1.79
- Brain - Caudate (basal ganglia)1.48
- Cervix - Ectocervix1.46
- Brain - Frontal Cortex (BA9)1.32
- Brain - Cortex1.31
- Brain - Putamen (basal ganglia)1.09
- Stomach1.04
- Adipose - Subcutaneous0.92
- Lung0.77
- Fallopian Tube0.76
- Brain - Anterior cingulate cortex (BA24)0.76
- Uterus0.76
- Nerve - Tibial0.68
- Brain - Hypothalamus0.66
- Kidney - Medulla0.62
- Cervix - Endocervix0.57
- Vagina0.55
And 29 more, listed on the interactive page.
- GO:0007187
- GO:0007193
- GO:0007198
- GO:0007268
- GO:0071312
- GO:0071466
- GO:1904707
Cellular components
- GO:0005886
- GO:0001586
- GO:0004993
- GO:0005515
decreased anxiety
- Inhibition/Decrease/Downregulation: acute
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased anxiety
- nervous system
- cardiovascular
PubMed 28216264decreased memory
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased memory
- nervous system
- cardiovascular
PubMed 28216264decreased pain
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased pain
- nervous system
- cardiovascular
PubMed 28216264increased memory
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased memory
- nervous system
- cardiovascular
PubMed 28216264increased aggression
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased aggression
- nervous system
- cardiovascular
PubMed 28216264increased blood pressure
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased blood pressure
- nervous system
- cardiovascular
PubMed 28216264decreased body temperature
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased body temperature
- nervous system
- cardiovascular
PubMed 28216264decreased aggression
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased aggression
- nervous system
- cardiovascular
PubMed 28216264decreased eating
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased eating
- nervous system
- cardiovascular
PubMed 28216264
cerebral and coronary artery vasoconstriction
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: cerebral and coronary artery vasoconstriction
- cardiovascular system
- central nervous system
PubMed 23197038increased aggression
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: increased aggression
- cardiovascular system
- central nervous system
PubMed 23197038increased blood pressure
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: increased blood pressure
- cardiovascular system
- central nervous system
PubMed 23197038
Related records
Trials (273)
- "Completeness of Response" Following Treatment With Treximetâ„¢ for Migraine
- A 1-year Study in Adolescents to Assess the Long-term Safety of Almotriptan Malate When Treating Their Migraine Headaches
- A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache
- A Comparison of the Efficacy of Amisulpride and Placebo in the Prevention of PONV in Patients at Moderate-to-high Risk of PONV.
- A Controlled Trial to Investigate the Efficacy and Safety of Frovatriptan to Prevent Menstrual Migraine
- A Dose-Finding Study of MK0974 in Acute Migraine (MK0974-004)
- A Double Blind Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Frovatriptan in the Acute Treatment of Migraine
- A Four-way Crossover Study of 3 Formulations of M207 With Intranasal Zolmitriptan in Healthy Volunteers
- A Pharmacokinetic Study to Evaluate TREXIMET in Adolescents With Migraine and Healthy Subjects Administered at Three Doses.
- A Pilot Study to Evaluate Barhemsys for the Prevention of Postoperative Nausea And Vomiting in the Bariatric Surgery Population
- A Randomized Trial of Frovatriptan for the Intermittent Prevention of Menstrual Migraine
- A Research Study to Compare the Treatments of a Combination of Elzasonan With Zoloft, to Zoloft Alone, or Placebo in People With Major Depressive Disorder (MDD)
- A Research Study To Evaluate If Frovatriptan Is Safe And Effective In Preventing Migraine Headache After Fasting
- A Study of 3 Dosage Strengths of Almotriptan Malate (AXERT®) in the Treatment of Acute Migraine in Adolescents
- A Study of ANAVEX3-71 in Adults With Schizophrenia
- A Study of HS-10353 in Adult Participants With Major Depressive Disorder
- A Study of Lasmiditan When Given With Sumatriptan in Healthy Participants
- A Study of M207 With Intranasal Zolmitriptan in Healthy Volunteers
- A Study of Rizatriptan Co-Administered With Acetaminophen for the Treatment of Acute Migraine
- A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis
Drugs (25)
- Almotriptan Serotonin 1b (5-HT1b) receptor agonist
- Almotriptan malate Serotonin 1b (5-HT1b) receptor agonist
- Amisulpride Serotonin (5-HT) receptor antagonist
- Dexfenfluramine Serotonin (5-HT) receptor agonist
- Dexfenfluramine hydrochloride Serotonin (5-HT) receptor agonist
- Donitriptan Serotonin 1b (5-HT1b) receptor agonist
- Eletriptan Serotonin 1b (5-HT1b) receptor agonist
- Eletriptan hydrobromide Serotonin 1b (5-HT1b) receptor agonist
- Elzasonan Serotonin 1b (5-HT1b) receptor antagonist
- Elzasonan hydrochloride Serotonin 1b (5-HT1b) receptor antagonist
- Ergoloid Serotonin 1b (5-HT1b) receptor agonist
- Ergoloid mesylates Serotonin 1b (5-HT1b) receptor agonist
- Frovatriptan Serotonin 1b (5-HT1b) receptor agonist
- Frovatriptan succinate Serotonin 1b (5-HT1b) receptor agonist
- GSK163090 Serotonin 1b (5-HT1b) receptor antagonist
- Naratriptan Serotonin 1b (5-HT1b) receptor agonist
- Naratriptan hydrochloride Serotonin 1b (5-HT1b) receptor agonist
- Rizatriptan Serotonin 1b (5-HT1b) receptor agonist
- Rizatriptan benzoate Serotonin 1b (5-HT1b) receptor agonist
- Sumatriptan Serotonin 1b (5-HT1b) receptor agonist